Johnson Y.n. Lau

Biography

Johnson is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management. As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in US history. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals . Prior, Johnson served as the Senior Director of Antiviral Therapy at Schering-Plough. Johnson has contributed more than 250 scientific publications and editorials/reviews/chapters in peer reviewed scientific journals and has edited two books . He was a former Managing Director at Roth Capital Partners, a Director of the Board of Chelsea Therapeutics (CHTP), serving as the Chair of the Audit and Finance Committee . He is also an Executive Board Member of the charity Project Vision . He is a Honorary professor/adjunct professor of the University of Hong Kong and Hong Kong Polytechnic University and a member of the Advisory Board of the School of Biomedical Sciences of the Chinese University of Hong Kong . Johnson received his medical degree (MBBS) and medical doctorate degree (MD) from the University of Hong Kong. He is also a Fellow of the Royal College of Physicians. Johnson has served as the Chairman of the Board of Athenex since its inception and assumed the role of CEO in mid 2011 . 

Research Interest

Scientific and Business Management. And Physics